Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Tirzepatide vs Retatrutide
Peptide Schedule Research TeamReviewed Sep 24, 202615 Citations
Tirzepatide (Zepbound, Mounjaro) is an FDA-approved GIP and GLP-1 receptor agonist. Retatrutide, also from Eli Lilly, is an investigational triple agonist that adds the glucagon receptor. No head-to-head trial has been published, so every number below comes from separate trials.
20.2% body weight gone at 72 weeks, and that was the average, not the ceiling. Tirzepatide (LY3298176, CAS 2023788-19-2) is a 39-amino acid acylated lipopeptide sold as Zepbound for obesity and Mounjaro for type 2 diabetes. It activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously. The dual receptor mechanism separates tirzepatide from single-target GLP-1 drugs like semaglutide. GIP receptor activation improves fat metabolism and may reduce the nausea burden that limits GLP-1-only treatment. GLP-1 receptor activation suppresses appetite, slows gastric emptying, and boosts insulin secretion. Those two pathways working together produce weight loss and glycemic control that neither achieves alone. SURMOUNT-1 (PMID 35658024, n=2,539) showed dose-dependent results at 72 weeks. Its treatment-regimen estimand counts everyone randomized, including people who stopped the drug. On that basis, mean weight loss was 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, versus 3.1% on placebo. SURMOUNT-5 (PMID 40353578, n=751) ran a direct comparison; tirzepatide reached 20.2% versus semaglutide's 13.7%. Roughly one in five tirzepatide patients lost 30% or more of their body weight. The r/Zepbound community (180,000+ members) confirms what the trials found. Appetite suppression starts within days. Most users stabilize at 7.5 to 12.5 mg rather than pushing to the maximum 15 mg dose. Cost and insurance coverage remain the biggest barriers. Weight regain after stopping is well-documented; about two-thirds of lost weight returns within a year of discontinuation.
View full guide →25.0% mean body weight lost at 80 weeks on 12 mg in TRIUMPH-1 (n=2,339, NEJM 2026, PMID 42814954), vs 3.9% on placebo. That peer-reviewed analysis counts everyone randomized, including people who stopped the drug, so it runs lower than on-treatment toplines. The smaller TRIUMPH-4 trial (n=445, December 2025) enrolled adults with obesity and knee osteoarthritis. Its Lilly topline reported 28.7% at 68 weeks and has not been peer-reviewed. No head-to-head trial against tirzepatide or semaglutide exists yet. The retatrutide peptide (LY3437943, CAS 2381089-83-2) is a 39-amino-acid synthetic lipopeptide developed by Eli Lilly. Known in community forums as reta peptide or Triple G, it activates GLP-1, GIP, and glucagon receptors simultaneously in a single molecule. The GLP-1 component suppresses appetite and slows gastric emptying. GIP improves insulin response and buffers GLP-1 tolerability. Glucagon raises resting energy expenditure and burns liver fat directly. That third receptor is the differentiator; dual agonists like tirzepatide lack it entirely. Clinicians and researchers tracking the obesity pharmacotherapy space have been watching retatrutide since the Phase 2 readout (Jastreboff et al., NEJM 2023, PMID 37366315), where 338 adults lost up to 24.2% body weight at 48 weeks on the 12 mg dose. A substudy of that trial in 98 adults with MASLD (Nature Medicine 2024, PMID 38858523) tracked liver fat. On 12 mg, it fell 82.4% from baseline by week 24. More Phase 3 results landed in 2026. In adults with type 2 diabetes, TRIUMPH-2 (n=1,152) found 18.8% weight loss on 12 mg vs 5.1% on placebo at 80 weeks (Lancet 2026, PMID 42810372). TRIUMPH-3, in adults with established cardiovascular disease, reported 22.6% in a Lilly topline (July 2026). Community interest runs highest among people who plateaued on semaglutide or tirzepatide. The enthusiasm is high; so are the GI side effects during dose escalation. Lilly plans to submit a Biologics License Application (BLA) to the FDA in Q1 2027. Until approval, retatrutide carries no FDA approval and no insurance coverage.
View full guide →At a Glance
| Attribute | ||
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Safety Grade | A | B |
| Half-Life | ~5 days | ~6 days |
| Route | Subcutaneous | Subcutaneous |
| Vial Sizes | 5 mg, 10 mg, 15 mg | 5 mg, 10 mg, 15 mg |
| Beginner Dose | 2.5 mg Weekly | 1 mg Weekly |
| Moderate Dose | 5 mg Weekly | 4 mg Weekly |
| Aggressive Dose | 15 mg Weekly | 12 mg Weekly |
| Dosing Source | FDA Label | Clinical Trial |
| Side Effects | Tirzepatide carries a black box warning for thyroid C-cell tumors. In rodent studies, it caused dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). Whether this translates to humans is unknown, and no confirmed human cases have been attributed to tirzepatide. The drug is contraindicated in anyone with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Gastrointestinal side effects are the most common reason people struggle with tirzepatide. In the SURMOUNT and SURPASS trials, nausea affected 12 to 29% of patients (dose-dependent, worst at higher weight-management doses). Diarrhea occurred in 13 to 17%. Vomiting hit 8 to 10%. Constipation affected 7 to 11%. Most of these effects are mild-to-moderate and improve with slow dose titration; the community-preferred 6 to 8 week steps between dose increases reduce GI burden compared to the FDA label's 4-week minimum. Decreased appetite (9 to 11%) is technically a side effect, though most users consider it the primary benefit. Sulfur burps are a community-reported nuisance during escalation phases that clinical trials don't track well. Hair thinning (telogen effluvium) affects roughly 4 to 5% of users versus about 1% on placebo. This isn't a direct drug effect. Rapid weight loss and caloric restriction trigger a hair growth cycle shift that typically starts 2 to 3 months in and resolves on its own by month 9 to 12. Injection-site reactions occur in 4 to 7% of patients. Rotating injection sites between the abdomen, thigh, and upper arm helps. Let the vial reach room temperature for 15 to 20 minutes before injecting. Pancreatitis is rare but serious. Severe, persistent abdominal pain warrants immediate medical evaluation. Serum lipase testing should happen only when pancreatitis is clinically suspected; routine screening isn't indicated. Gallbladder disease and hypersensitivity reactions are uncommon but documented in clinical trials. Stop tirzepatide and seek medical care if you develop signs of anaphylaxis, severe abdominal pain, or jaundice. Low blood pressure is a smaller but real signal. On the Zepbound label, hypotension hit 1.6% on tirzepatide vs 0.1% on placebo in the pooled weight-loss trials. It ran higher in people also taking blood pressure medication (2.2% vs 1.2% without it) and showed up alongside gastrointestinal side effects and dehydration. A 2026 meta-analysis pooled 32 randomized trials of tirzepatide and semaglutide (47,332 people, PMID 42603240). Tirzepatide carried 2.45 times the risk of hypotension-related events (95% CI 1.35 to 4.45). The risk rose at higher doses, and semaglutide showed no significant change. Lightheadedness when you stand up is worth a blood pressure check, especially if you take antihypertensives. Muscle loss is a legitimate concern. Approximately 25% of weight lost on tirzepatide is lean mass (SURMOUNT-1 body composition data). Resistance training 3 to 4 times per week and protein intake of at least 1.2 g/kg body weight per day are the primary countermeasures. Pregnancy and breastfeeding: tirzepatide is contraindicated. Stop treatment at least 2 months before planned conception due to the 5-day half-life and limited reproductive safety data. | Gastrointestinal events during dose escalation are the defining tolerability challenge with retatrutide. Community users often describe them as rougher than on other GLP-1 drugs, though no head-to-head trial has tested that. In TRIUMPH-4 Phase 3 data (Lilly topline 2025), nausea occurred in 38 to 43% of participants. Diarrhea affected 33 to 35%. Constipation hit 22 to 25%. Vomiting was reported in 21%. Side effects led 12.2% on 9 mg and 18.2% on 12 mg to stop, vs 4.0% on placebo. These rates are dose-dependent and front-loaded, meaning they peak during the weeks immediately after each dose increase. Most GI events resolve within 1 to 2 weeks at a stable dose. Stepping up slowly, with 4 weeks between escalations as the Phase 3 trials do, is the standard way to limit them. Raised resting heart rate is the second signal that deserves attention. Phase 2 trials (PMID 37366315) documented a dose-dependent increase in resting HR tied to glucagon receptor activation. Community users at 8 mg and above have reported palpitations and sustained HR above 90 bpm. The TRIUMPH-1 and TRIUMPH-2 abstracts report no heart rate figures, so anyone with a cardiac history should track heart rate weekly during titration. Do not escalate if resting HR stays above 100 bpm. Dysesthesia is the newer Phase 3 signal. It means abnormal skin sensations such as tingling, burning, or numbness. In TRIUMPH-4 it showed up in 8.8% on 9 mg and 20.9% on 12 mg, vs 0.7% on placebo. TRIUMPH-1 reported 5.1 to 12.5% across the 4, 9, and 12 mg doses, vs 0.9% on placebo. Most cases were mild to moderate and resolved during treatment (Lilly topline figures; the TRIUMPH-1 NEJM abstract does not give dysesthesia rates). TRIUMPH-2 (Lancet 2026, PMID 42810372), in 1,152 adults with obesity and type 2 diabetes, flagged low blood pressure. Hypotension hit 1%, 5%, and 6% on 4, 9, and 12 mg vs under 1% on placebo. Dysesthesia ran 4 to 7% vs 1%. Gastrointestinal events were still the most frequent: diarrhea hit 27 to 34% vs 13% on placebo, and nausea 14 to 28% vs 8%. Stopping for side effects or death ran 12% on 9 mg and 8% on 12 mg, vs 4% on 4 mg and 5% on placebo. Lightheadedness on standing is worth a blood pressure check. Post-injection fatigue, sometimes called "wipeout day," shows up consistently in community reports at doses of 8 mg or higher. Users describe pronounced fatigue lasting 12 to 24 hours after injection, particularly during the first 2 to 4 weeks at a new dose level. Scheduling the injection on a low-demand day helps. The GLP-1 class carries an unresolved rodent thyroid C-cell tumor signal. No confirmed human thyroid cancer risk has been established for any GLP-1 agonist, but retatrutide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Pancreatitis is a known class risk. Severe persistent abdominal pain radiating to the back warrants immediate medical attention and discontinuation. Pregnancy is an absolute contraindication. No human pregnancy data have been published for retatrutide. Discontinue well before any planned pregnancy. Product quality adds a layer of risk specific to investigational peptides. Retatrutide is not FDA approved; compounded versions lack standardized formulation. A Certificate of Analysis with HPLC purity data is the only check on each batch. Grey-market research chemicals carry contamination and identity risks that cannot be verified. |
Key Differences
Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide activates those two plus the glucagon receptor [2]. Both are once-weekly subcutaneous injections made by Eli Lilly.
SURMOUNT-1 (NEJM 2022)[1] enrolled 2,539 adults with obesity or overweight and no diabetes. Weight fell 15.0%, 19.5% and 20.9% on tirzepatide 5, 10 and 15 mg over 72 weeks, vs 3.1% on placebo. TRIUMPH-1 (NEJM 2026)[2] enrolled 2,339 adults with obesity and no diabetes. Retatrutide 4, 9 and 12 mg produced 17.6%, 23.7% and 25.0% over 80 weeks, vs 3.9% on placebo.
The two trials ran 72 and 80 weeks and started years apart. So the gap between 20.9% and 25.0% is an estimate, not a measured difference. Both figures count everyone randomized, including people who stopped the drug.
Weight loss runs lower on both drugs in type 2 diabetes. SURMOUNT-2 [3] reported 12.8% on tirzepatide 10 mg and 14.7% on 15 mg at 72 weeks, vs 3.2% on placebo. TRIUMPH-2 [4] enrolled 1,152 adults and reported 11.9%, 16.8% and 18.8% on retatrutide 4, 9 and 12 mg at 80 weeks, vs 5.1%.
No head-to-head result has been published yet. TRIUMPH-5 (NCT06662383), a phase 3 trial of retatrutide vs tirzepatide in about 800 adults with obesity, is still running. Tirzepatide has beaten another drug head-to-head: 20.2% vs 13.7% weight loss against semaglutide in SURMOUNT-5 [5]. In a phase 2 diabetes trial, retatrutide 12 mg lowered HbA1c more than dulaglutide 1.5 mg at 24 weeks (2.02 vs 1.41 points)[6].
Both have sleep apnea data, and only tirzepatide has the indication. Zepbound is FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity. In its two 52-week label trials, the apnea-hypopnea index (AHI) fell by 25.3 and 29.3 events per hour, vs 5.3 and 5.5 on placebo. TRIUMPH-1 included 243 people with sleep apnea; on retatrutide 9 and 12 mg, AHI fell by 34.3 and 32.1, vs 9.6 on placebo. The trials differ in length and enrollment, so these drops do not rank the drugs.
The liver trials measured different things. A phase 2 trial (NEJM 2024)[7] enrolled 190 adults with biopsy-confirmed MASH and moderate or severe fibrosis. After 52 weeks, MASH resolved without worse fibrosis in 44 to 62% on tirzepatide vs 10% on placebo. Retatrutide's phase 2a substudy [8] tracked liver fat by imaging in 98 people; on 12 mg it fell 82.4% at 24 weeks. Neither drug has an FDA liver indication.
Gastrointestinal events were the most common side effects in SURMOUNT-1 [1] and in TRIUMPH-1 [2]. The Zepbound label reports a mean heart rate rise of 1 to 3 beats per minute. In retatrutide's phase 2 trial, the rise grew with dose, peaked at 24 weeks, then declined [9].
Two side effects stand out in retatrutide's phase 3 data. In TRIUMPH-2, dysesthesia (abnormal skin sensation) hit 4 to 7% vs 1% on placebo [4]. Low blood pressure hit 1 to 6% vs under 1%. The Zepbound label lists dysesthesia at 0.2 to 0.4% and low blood pressure at 1.6%, vs 0.1% on placebo for each. The trials enrolled different people, so these rates do not rank the drugs.
Tirzepatide holds two FDA approvals: Mounjaro for type 2 diabetes on May 13, 2022, and Zepbound for weight management on November 8, 2023. Retatrutide has no FDA approval and is still in phase 3 trials.
Community reports describe retatrutide as the step people take after a tirzepatide plateau. Users report faster appetite suppression, rougher nausea during dose steps and a raised resting heart rate. On tirzepatide, many stretch each four-week step to six to eight weeks to ease nausea. Any retatrutide taken outside a trial comes from unregulated sources, so its identity and purity cannot be checked.
When to Choose Tirzepatide
An FDA-approved drug with a prescription path is required (Zepbound for weight, Mounjaro for type 2 diabetes)
Obstructive sleep apnea with obesity is also being treated (on the Zepbound label only)
Heart attack and stroke risk in type 2 diabetes is a concern (on the Mounjaro label, from SURPASS-CVOT)[10]
A product with known identity and purity matters more than the last few points of weight loss
When to Choose Retatrutide
A clinical trial is an option (retatrutide has no FDA approval)
Weight loss stalled on tirzepatide, a common story in community reports, and a clinical trial is an option
Liver fat is the focus (down 82.4% at 24 weeks on 12 mg in phase 2a)[8], and a clinical trial is an option
Verdict
In separate trials, retatrutide produced more weight loss: 25.0% at 80 weeks in TRIUMPH-1 against 20.9% at 72 weeks for tirzepatide in SURMOUNT-1. Tirzepatide is the one with FDA approval, a sleep apnea indication, a heart indication in type 2 diabetes and a biopsy-based liver trial. Community reports treat retatrutide as the next step after a tirzepatide plateau, with rougher nausea during dose steps. Outside a trial, retatrutide comes only from unregulated sources. Until TRIUMPH-5, the head-to-head trial, reports, the size of the gap stays an estimate.
Research peptides with both sides of the evidence.
Published studies and community reports, side by side, for 150+ peptides. Save the ones you are weighing and see when anything changes.
Can You Stack Tirzepatide + Retatrutide?
Not together. Retatrutide already activates the GIP and GLP-1 receptors that tirzepatide targets, so the pair doubles up on both. The Zepbound label says coadministration with any GLP-1 receptor agonist is not recommended. No trial has tested the pair.
Dosage Calculators
Or use the universal Peptide Calculator for any peptide.
Related Comparisons
Related Guides & Stacks
Peptide Schedule Research TeamReviewed Sep 24, 202615 Citations
References
- [1]SURMOUNT-1: tirzepatide once weekly for obesity, 72 weeks (NEJM 2022) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]TRIUMPH-1: retatrutide for obesity, 80 weeks (NEJM 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]SURMOUNT-2: tirzepatide once weekly for obesity in type 2 diabetes, 72 weeks (Lancet 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]TRIUMPH-2: retatrutide in adults with obesity and type 2 diabetes, 80 weeks (Lancet 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]SURMOUNT-5: tirzepatide vs semaglutide for obesity, 72 weeks (NEJM 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]Retatrutide vs placebo and dulaglutide 1.5 mg in type 2 diabetes, phase 2 (Rosenstock et al., Lancet 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [7]SYNERGY-NASH: tirzepatide for MASH with moderate or severe fibrosis, phase 2, 52 weeks (Loomba et al., NEJM 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [8]Retatrutide and liver fat: phase 2a substudy in metabolic dysfunction-associated steatotic liver disease (Nat Med 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [9]Retatrutide for obesity, phase 2, 48 weeks (Jastreboff et al., NEJM 2023) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [10]SURPASS-CVOT: cardiovascular outcomes with tirzepatide vs dulaglutide in type 2 diabetes (NEJM 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Zepbound (tirzepatide) prescribing information, DailyMed (opens in a new tab)FDA Label
- Mounjaro (tirzepatide) prescribing information, DailyMed (opens in a new tab)FDA Label
- Drugs@FDA: Mounjaro, NDA 215866 (approved May 13, 2022) (opens in a new tab)FDA Label
- Drugs@FDA: Zepbound, NDA 217806 (approved November 8, 2023) (opens in a new tab)FDA Label
- ClinicalTrials.gov NCT06662383: TRIUMPH-5, retatrutide vs tirzepatide in adults with obesity, phase 3 (active, no results posted) (opens in a new tab)Clinical Trial